Literature DB >> 17430678

The management of functional mitral regurgitation.

Blase A Carabello1.   

Abstract

Mitral regurgitation (MR) may be classified into two major categories: primary and secondary (functional). In primary MR, disease of the valve itself (eg, myxomatous degeneration, rheumatic disease) causes valve incompetence, producing left ventricular (LV) volume overload. To compensate, the left ventricle must enlarge in order to increase its volume-pumping capacity. If volume overload is prolonged and severe, the adverse effects of remodeling together with activation of deleterious neurohumoral systems leads to myocardial damage. It is quite clear that correction of the volume overload causes myocardial healing and reverse remodeling. Conversely, in secondary MR, the valve itself is normal. Ventricular dilatation and wall motion abnormalities cause papillary muscle displacement and annular dilatation, causing a normal mitral valve to leak. In this situation it is not clear whether or when correction of the MR is beneficial because the MR was not the primary cause of the LV dysfunction to begin with. Other areas of uncertainty include the type of correction to be used and whether burgeoning technologies for percutaneous valve repair will be useful.

Entities:  

Mesh:

Year:  2007        PMID: 17430678     DOI: 10.1007/bf02938337

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  41 in total

1.  Effect of angiotensin-converting enzyme inhibitor therapy in mitral regurgitation with normal left ventricular function.

Authors:  F Marcotte; G N Honos; A D Walling; D Beauvais; M J Blais; C Daoust; A Lisbona; J L McCans
Journal:  Can J Cardiol       Date:  1997-05       Impact factor: 5.223

2.  Hemodynamic predictors of outcome in patients undergoing valve replacement.

Authors:  B A Carabello; H Williams; A K Gash; R Kent; D Belber; A Maurer; J Siegel; K Blasius; J F Spann
Journal:  Circulation       Date:  1986-12       Impact factor: 29.690

3.  Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT.

Authors:  S Thackray; K Witte; A L Clark; J G Cleland
Journal:  Eur J Heart Fail       Date:  2000-06       Impact factor: 15.534

4.  Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.

Authors:  J N Cohn; S Ziesche; R Smith; I Anand; W B Dunkman; H Loeb; G Cintron; W Boden; L Baruch; P Rochin; L Loss
Journal:  Circulation       Date:  1997-08-05       Impact factor: 29.690

5.  Ischemic mitral regurgitation: revascularization alone versus revascularization and mitral valve repair.

Authors:  Yong-Hwan Kim; Lawrence S C Czer; Harmik J Soukiasian; Michele De Robertis; Kathy E Magliato; Carlos Blanche; Sharo S Raissi; James Mirocha; Robert J Siegel; Robert M Kass; Alfredo Trento
Journal:  Ann Thorac Surg       Date:  2005-06       Impact factor: 4.330

6.  Ischemic mitral valve regurgitation grade II-III: correction in patients with impaired left ventricular function undergoing simultaneous coronary revascularization.

Authors:  E Prifti; M Bonacchi; G Frati; G Giunti; G Babatasi; G Sani
Journal:  J Heart Valve Dis       Date:  2001-11

7.  Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure.

Authors:  Benjamin H Trichon; G Michael Felker; Linda K Shaw; Christopher H Cabell; Christopher M O'Connor
Journal:  Am J Cardiol       Date:  2003-03-01       Impact factor: 2.778

8.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

9.  Mitral valve replacement with and without chordal preservation in patients with chronic mitral regurgitation. Mechanisms for differences in postoperative ejection performance.

Authors:  J D Rozich; B A Carabello; B W Usher; J M Kratz; A E Bell; M R Zile
Journal:  Circulation       Date:  1992-12       Impact factor: 29.690

10.  Diagnostic and therapeutic considerations in acute, severe mitral regurgitation: experience in 42 consecutive patients entering the intensive care unit with pulmonary edema.

Authors:  D Horstkotte; H D Schulte; R Niehues; R M Klein; C Piper; B E Strauer
Journal:  J Heart Valve Dis       Date:  1993-09
View more
  6 in total

Review 1.  Surgical approach to mitral regurgitation in chronic heart failure: when is it an option?

Authors:  Juan A Crestanello
Journal:  Curr Heart Fail Rep       Date:  2012-03

2.  Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction.

Authors:  Alessandra Meris; Maria Amigoni; Anil Verma; Jens Jakob Thune; Lars Køber; Eric Velazquez; John J V McMurray; Marc A Pfeffer; Robert Califf; Robert A Levine; Scott D Solomon
Journal:  J Am Soc Echocardiogr       Date:  2012-02-04       Impact factor: 5.251

3.  [Mitral regurgitation in heart failure. Surgical therapy].

Authors:  H Aubin; H Kamiya; A Lichtenberg
Journal:  Herz       Date:  2013-03       Impact factor: 1.443

4.  Quantitative evaluation of change in coexistent mitral regurgitation after aortic valve replacement.

Authors:  David J Kaczorowski; John W Macarthur; Jessica Howard; Dale Kobrin; Alex Fairman; Y Joseph Woo
Journal:  J Thorac Cardiovasc Surg       Date:  2012-12-11       Impact factor: 5.209

5.  Reduced systolic torsion in chronic "pure" mitral regurgitation.

Authors:  Daniel B Ennis; Tom C Nguyen; Akinobu Itoh; Wolfgang Bothe; David H Liang; Neil B Ingels; D Craig Miller
Journal:  Circ Cardiovasc Imaging       Date:  2009-01-22       Impact factor: 7.792

6.  Cardiomyocyte mitochondrial oxidative stress and cytoskeletal breakdown in the heart with a primary volume overload.

Authors:  Danielle M Yancey; Jason L Guichard; Mustafa I Ahmed; Lufang Zhou; Michael P Murphy; Michelle S Johnson; Gloria A Benavides; James Collawn; Victor Darley-Usmar; Louis J Dell'Italia
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-01-16       Impact factor: 4.733

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.